A-1331852

製品コードS7801 バッチS780102

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C38H38N6O3S
分子量 658.81 CAS No. 1430844-80-6
Solubility (25°C)* 体外 DMSO 100 mg/mL (151.78 mM)
Water Insoluble
Ethanol Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 A-1331852 is a potent and selectiveBCL-XL inhibitor and may be useful in the treatment of cancer, immune and autoimmune diseases.
in vitro A-1331852 exhibits remarkable potency both as a single agent and in combination with TKIs in killing primary CD34+ CML cell. Also, It has remarkable potency in inducing apoptosis in these cells at low nanomolar concentrations as early as 1 h post-treatment[2].
in vivo A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent[1].

プロトコル(参考用のみ)

細胞アッセイ 細胞株 K562 cells
濃度 100 nM
反応時間 0-2 h
実験の流れ Immunoprecipitation of BCL-XL is carried out in K562 cells, exposed to A-1331852 (100 nM) for 0-2 h, and the eluted complexes are immunoblotted for the indicated proteins. The input cell lysates and the immunodepleted supernatant (labeled as Flow-through) are immunoblotted to check the efficiency of the immunoprecipitation.
動物実験 動物モデル SCID and SCID-bg mice
投薬量 25 mg/kg
投与方法 Oral administration

参考

  • https://pubmed.ncbi.nlm.nih.gov/25787766/
  • https://pubmed.ncbi.nlm.nih.gov/26987906/

カスタマーフィードバック

Data from [Data independently produced by , , Cancer Lett, 2018, 412:131-142]

Data from [Data independently produced by , , Mol Cancer Res, 2016, 14(12):1176-1181]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo [ Cell, 2025, S0092-8674(25)00689-0] PubMed: 40645177
Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors [ Mol Cancer, 2025, 24(1):154] PubMed: 40442785
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia [ Haematologica, 2025, 110(1):78-91] PubMed: 39113656
Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies [ Cell Death Discov, 2025, 11(1):91] PubMed: 40055336
Bcl‑xL‑specific BH3 mimetic A‑1331852 suppresses proliferation of fluorouracil‑resistant colorectal cancer cells by inducing apoptosis [ Oncol Rep, 2025, 53(2)26] PubMed: 39717947
Cul5 Wsb2 uses BCL2 proteins as co-receptors to target Bim for degradation [ bioRxiv, 2025, 2025.08.14.670414] PubMed: 40832228
Tumor nutrient stress gives rise to a drug tolerant cell state in pancreatic cancer [ bioRxiv, 2025, 2025.09.04.673818] PubMed: 40964288
Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models [ Cancer Res Commun, 2025, 5(8):1396-1408] PubMed: 40704654
HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells [ Cell Death Differ, 2024, 10.1038/s41418-024-01417-z] PubMed: 39627361
Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome [ Cell Death Dis, 2024, 15(5):323] PubMed: 38724507

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。